POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining cellular membrane potential, nerve impulse conduction, muscle contraction, and acid-base balance. Dextrose is a carbohydrate that provides calories and may help prevent ketosis. Sodium chloride provides sodium and chloride ions, which are critical for extracellular fluid balance and osmotic pressure.
| Metabolism | Potassium is not metabolized; it is excreted primarily by the kidneys. Dextrose is metabolized via glycolysis and the citric acid cycle. Sodium and chloride are not metabolized. |
| Excretion | Renal excretion of potassium (90%) and chloride (95%); negligible biliary/fecal elimination. Dextrose and sodium chloride components are metabolized and excreted renally. |
| Half-life | Potassium: ~12 hours (terminal half-life) in patients with normal renal function; prolonged in renal impairment. Dextrose and sodium chloride: minutes to hours depending on metabolic state. |
| Protein binding | Potassium: <2% bound; chloride: minimal binding; dextrose and sodium not protein-bound. |
| Volume of Distribution | Potassium: 0.5-0.7 L/kg (total body water). Chloride: 0.2-0.3 L/kg (extracellular fluid). Dextrose: 0.2-0.3 L/kg (extracellular fluid initially, then intracellular metabolism). |
| Bioavailability | Intravenous: 100% bioavailable. Not administered orally for this formulation. |
| Onset of Action | Intravenous: rapid (within minutes) for electrolyte effects; dextrose utilization begins immediately. |
| Duration of Action | Intravenous: 1-2 hours for electrolyte correction; dextrose effects last until metabolized (typically minutes to hours). Clinical monitoring is required. |
Intravenous infusion; rate not to exceed 10 mEq/h potassium; typical adult dose: 20-40 mEq potassium per liter of IV fluid, administered at 100-200 mL/h, based on electrolyte needs.
| Dosage form | INJECTABLE |
| Renal impairment | GFR >50 mL/min: no adjustment; GFR 30-50 mL/min: reduce potassium to 50% of standard dose; GFR <30 mL/min: contraindicated unless monitored closely with serum potassium. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: monitor potassium and reduce dose if needed; Child-Pugh Class C: use with caution, typically reduce dose by 50% due to risk of hyperkalemia. |
| Pediatric use | Weight-based: 0.5-1 mEq/kg per day potassium, infused at a rate not exceeding 0.5 mEq/kg/h; max 3 mEq/kg/day; adjust fluid rate for dextrose and sodium based on age and clinical status. |
| Geriatric use | Elderly patients: start at lower end of dosing range (e.g., 20 mEq potassium per liter), infuse at slower rate (max 5 mEq/h), monitor renal function and serum potassium frequently due to decreased renal reserve. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium, sodium, chloride, and glucose are normal constituents of breast milk. No specific M/P ratio is available; however, concentrations are similar to maternal plasma. Intravenous infusion of these electrolytes at physiological doses is considered compatible with breastfeeding. Caution with high doses may alter milk electrolyte content. |
| Teratogenic Risk |
■ FDA Black Box Warning
Potassium chloride concentrate for injection must be diluted before use. Administration of undiluted potassium chloride may cause cardiac arrest and death.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia (serum potassium >5.0 mEq/L)","Severe renal impairment with oliguria or anuria","Concurrent use of potassium-sparing diuretics or ACE inhibitors (relative)","Addison's disease","Acute dehydration or heat cramps","Hyperchloremia or hypernatremia (relative)"]
| Precautions | ["Hyperkalemia: Can cause cardiac arrest; monitor serum potassium levels and ECG during administration.","Dilution required: Concentrated potassium chloride must be diluted to avoid fatal hyperkalemia.","Renal impairment: Use with caution; may lead to potassium accumulation.","Cardiac disease: Increased risk of arrhythmias; monitor closely.","Extravasation: Can cause tissue necrosis if potassium leaks into surrounding tissue.","Dextrose administration: May cause hyperglycemia; use with caution in diabetes."] |
Loading safety data…
| Potassium chloride, dextrose, and sodium chloride are essential nutrients; no teratogenic effects are expected at therapeutic doses. However, electrolyte imbalances (hyperkalemia, hypernatremia, hyperglycemia) may pose fetal risks, especially in the third trimester. Dextrose may cause fetal hyperinsulinemia and rebound hypoglycemia if maternal hyperglycemia occurs. First trimester: no known teratogenicity. Second and third trimesters: risks are related to maternal electrolyte disturbances rather than direct teratogenicity. |
| Fetal Monitoring | Monitor maternal serum electrolytes (potassium, sodium, chloride, glucose) and fluid balance. Assess fetal heart rate and uterine activity if administered during labor. Monitor for signs of hyperkalemia (ECG changes), hypernatremia, or fluid overload. In dextrose-containing solutions, monitor maternal blood glucose, especially in diabetes or gestational diabetes. |
| Fertility Effects | No known adverse effects on fertility at therapeutic doses. Electrolyte imbalances may impact ovulation and implantation, but this is unlikely with appropriate use. |